As of Friday close, 10x Genomics Inc.’s (NASDAQ:TXG) stock was down -$2.45, moving down -4.19 percent to $56.04. The average number of shares traded per day over the past five days has been 1,585,380 shares. 1 time new highs have been achieved over the past 5 days, with a -$6.87 fall in that time frame. In the last twenty days, the average volume was 1,047,695, while in the previous 50 days, it was 967,532.
Since last month, TXG stock rose 5.80%. Shares of the company fell to $52.01 on 07/06/23, the lowest level in the past month. A 52-week high of $63.57 was reached on 07/31/23 after having rallying from a 52-week low of $23.81. Since the beginning of this year, TXG’s stock price has risen by 53.79% or $19.60 and marked a new high 24 times. However, the stock has declined by -11.85% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
TXG stock investors should be aware that 10x Genomics Inc. (TXG) stock had its last reported insider trading activity 4 days ago on Aug 01. Hindson Benjamin J. disposed of 6,970 shares for $62.21 on Aug 01. It resulted in a $433,612 divestment by the insider. Saxonov Serge sold 40,000 shares at an average price of $60.03 on Jul 19. The insider now owns 869,850 shares following the transaction. On Jul 19, Hindson Benjamin J. sold 13,940 shares at $60.03 apiece. The transaction was valued at $836,834.
Valuation Metrics
The stock’s beta is 1.75. Besides these, the trailing price-to-sales (P/S) ratio of 11.72, the price-to-book (PB) ratio of 8.07.
Financial Health
In the three months ended June 29, 10x Genomics Inc.’s quick ratio stood at 4.60, while its current ratio was 5.40, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 75.60% percent. In the year ended June 29, EBITDA margin amounted to -25.31%, whereas operating margins totaled -33.20%. Based on annual data, TXG earned $396.02 million in gross profit and brought in $516.41 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -21.30%. Return on equity (ROE) for the past 12 months was -22.00%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. TXG’s revenue rose 13.74% to $131.07 million during the quarter, while net income inched up to $134.29 million. While analysts expected 10x Genomics Inc. to report -$0.4 quarterly earnings, the actual figure was -$0.53 per share, beating the consensus estimate by -32.50%. During the quarter, the company generated -$43.22 million in EBITDA. The liabilities of 10x Genomics Inc. were 211.65 million at the end of its most recent quarter ended June 29, and its total debt was $102.04 million. The value of shareholders’ equity is $116.19 million.
Technical Picture
This quick technical analysis looks at 10x Genomics Inc.’s (TXG) price momentum. With a historical volatility rate of 42.21%, the RSI 9-day stood at 33.84% on 04 August.
With respect to its five-day moving average, the current 10x Genomics Inc. price is down by -10.92% percent or -$6.87. At present, TXG shares trade +3.97% above its 20-day simple moving average and +17.90% percent above its 100-day simple moving average. However, the stock is currently trading approximately +5.10% above its SMA50 and +109.03% above its SMA200.
Stochastic coefficient K was 20.45% and Stochastic coefficient D was 43.12%, while ATR was 2.42. Given the Stochastic reading of 13.65% for the 14-day period, the RSI (14) reading has been calculated as 41.62%. As of today, the MACD Oscillator reading stands at -2.67, while the 14-day reading stands at -2.30.
Analyst Ratings
10x Genomics Inc. (TXG) has been rated Overweight by analysts. According to 1 brokerage firm, TXG is a sell, and 3 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate 10x Genomics Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $65.50, the current consensus forecast for the stock is $30.00 – $75.00. Based on these forecasts, analysts predict 10x Genomics Inc. (TXG) will achieve an average price target of $62.50.
